Key result
Apixaban plus a P2Y12 inhibitor ranked highest for safety outcomes including TIMI major bleeding compared to VKA plus a P2Y12 inhibitor, while maintaining comparable antithrombotic efficacy.
Why the study?
Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention faces major treatment problems in clinical practice.
Does the choice of antithrombotic regimen (NOAC vs VKA, dual vs triple therapy) reduce bleeding and prevent ischemic events in patients with atrial fibrillation undergoing percutaneous coronary intervention?
Meta-Analysis (n=11,532)
Yes
Does the choice of antithrombotic regimen (NOAC vs VKA, dual vs triple therapy) reduce bleeding and prevent ischemic events in patients with atrial fibrillation undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
In patients with atrial fibrillation undergoing PCI, apixaban plus a P2Y12 inhibitor appears to be the most favorable regimen for reducing bleeding risk without compromising antithrombotic efficacy.
Background: Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention is facing major treatment problems in clinical practice. Methods: We firstly conducted a Bayesian network meta-analysis to study the safety and efficacy of different antithrombotic regimens. Only randomized controlled trials from PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Embase, and China National Knowledge Infrastructure were included in our study. The Bayesian random-effects model was used in this study. The primary safety and efficacy outcomes were major bleeding according to the criteria of Thrombolysis In Myocardial Infarction (TIMI) and trial-defined major adverse cardiovascular events, respectively. The secondary safety outcomes were combined TIMI major and minor bleeding, trial-defined primary bleeding events, and intracranial hemorrhage. The secondary efficacy outcomes were all-cause or cardiovascular mortality, myocardial infarction, stroke, stent thrombosis, and hospitalization. Results: Total of 11,532 patients from the five randomized controlled trials were analyzed, of whom 8,426 were male. Compared with vitamin K antagonist (VKA) plus P2Y12 inhibitor, the odds ratios (95% credible intervals) for TIMI major bleeding were 1.70 (0.77-3.80) for VKA plus dual antiplatelet therapy (DAPT), 1.20 (0.30-4.60) for rivaroxaban plus P2Y12 inhibitor, 1.00 (0.25-3.90) for rivaroxaban plus DAPT, 0.76 (0.21-2.80) for dabigatran plus P2Y12 inhibitor, 0.71 (0.25-2.10) for apixaban plus P2Y12 inhibitor, 1.40 (0.52-3.80) for apixaban plus DAPT, and 1.00 (0.27-4.00) for edoxaban plus P2Y12 inhibitor. For trial-defined major adverse cardiovascular events, compared with VKA plus P2Y12 inhibitor, the odds ratios (95% credible intervals) were 1.10 (0.61-2.00) for VKA plus DAPT, 1.20 (0.45-3.70) for rivaroxaban plus P2Y12 inhibitor, 1.10 (0.38-3.20) for rivaroxaban plus DAPT, 1.10 (0.43-3.10) for dabigatran plus P2Y12 inhibitor, 1.00 (0.47-2.20) for apixaban plus P2Y12 inhibitor, 0.99 (0.46-2.20) for apixaban plus DAPT, and 1.20 (0.43-3.40) for edoxaban plus P2Y12 inhibitor. Apixaban plus P2Y12 inhibitor was the highest-ranking of safety outcomes and VKA plus P2Y12 inhibitor was the highest-ranking of efficacy outcomes other than trial-defined major adverse cardiovascular events. Conclusion: Apixaban plus P2Y12 inhibitor seems to be linked with fewer bleeding complications while retaining antithrombotic efficacy. Moreover, for most efficacy indicators, the ranking of VKA plus P2Y12 inhibitor is still very high. Systematic Review Registration: [www.crd.york.ac.uk/prospero/], identifier [CRD42020149894].
No takes yet. Share an insight, caveat, or question.
Liang et al. (2022) conducted a meta-analysis in Atrial fibrillation undergoing percutaneous coronary intervention (n=11,532). Apixaban plus P2Y12 inhibitor vs. VKA plus P2Y12 inhibitor was evaluated on TIMI major bleeding (OR 0.71, 95% CI 0.25-2.10). Apixaban plus a P2Y12 inhibitor ranked highest for safety outcomes including TIMI major bleeding compared to VKA plus a P2Y12 inhibitor, while maintaining comparable antithrombotic efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: